J.C. Bendell

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

J.C. Bendell, Eileen M. O’Reilly, Mark R. Middleton et al. · Annals of Oncology · 2015 · 96 citations · Full text

Medicine, Oncology, Pharmacology +13

BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

Dejan Juric, Jordi Rodón, AM Gonzalez-Angulo et al. · Cancer Research · 2012 · 39 citations

Medicine, Pharmacokinetics, Pharmacology +10

Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)

J.C. Bendell, Gail S. Eckhardt, H. S. Hochster et al. · European Journal of Cancer · 2016 · 32 citations

Medicine, Oncology, Pharmacology +10

525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies

Geoffrey Y. Ku, J.C. Bendell, A. W. Tolcher et al. · Annals of Oncology · 2020 · 28 citations

Medicine, Oncology, Pharmacology +15

11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

Josep Tabernero, Robin M.J.M. van Geel, J.C. Bendell et al. · European Journal of Cancer · 2014 · 10 citations

Medicine, Oncology, Pharmacology +12